Gastrointestinal Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Nina N. Grenon, DNP, AGCNP-BC, AOCN®
Dana-Farber Cancer Institute
J Adv Pract Oncol 2020;11(6):552-557 |
© 2020 Harborside™
Using coverage from The ASCO Post, Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates findings from two phase III trials, reviews takeaways from the final results of the IDEA study, and discusses what was learned about PARP inhibitor therapy from the TAPUR basket trial.
For access to the full length article, please sign in